Dexamethasone pulse therapy in pemphigus

Toth, GG; Meer, JB van de; Jonkman, Marcel F.

doi:10.1046/j.1468-3083.2002.00413.x

Cited by 33 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the exact explanation is not available, it has been seen that various side effects with conventional daily oral corticosteroids are infrequent when administered in pulse form. 15,16 Pharmacokinetic studies and studies of the effects of pulse corticosteroid therapy on various systems may help us to understand this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

Placebo-controlled oral pulse prednisolone therapy in alopecia areata

Kar

Handa

Dogra

et al. 2005

Journal of the American Academy of Dermatology

122

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Placebo-controlled oral pulse prednisolone therapy in alopecia areata

Kar

Handa

Dogra

et al. 2005

Journal of the American Academy of Dermatology

122

View full text Add to dashboard Cite

“…The patients sometimes benefit from high doses of oral corticosteroids [15]. However, pulse therapy with high doses of prednisolone (or DXM) in combination with other immunosuppressant agents like azathioprine, mycophenolate mofetyl or cyclophosphamide induces variable and inconstant results [6,10,11].…”

Section: Discussionmentioning

confidence: 99%

Follicular Non-Hodgkin's Lymphoma with Refractory Paraneoplastic Pemphigus: Case Report with Review of Novel Treatment Modalities

Rossum

Verhaegen

Jonkman

et al. 2004

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

In this paper a patient with a non-Hodgkin's lymphoma (NHL) and paraneoplastic pemphigus (PNP) is described. PNP is a very rare, painful mucocutaneous intraepithelial blistering disease associated with occult or confirmed malignancy. Patients with PNP show severe, progressive mucocutaneous disease with a high mortality rate, because of drug-induced infectious complications. The patients sometimes benefit from high doses of oral corticosteroids. However, pulse therapy with high doses of prednisolone (or dexamethasone) in combination with other immunosuppressants induces variable and inconstant results. Intravenous immunoglobulin (IVIg) has been applied in different cases of PNP with encouraging results. Plasmapheresis or plasma exchange (PE) in combination with corticosteroids and/or cyclophosphamide or azathioprine showed similar rapid and beneficial results in association with decreasing auto-antibody levels in this group of refractory pemphigus. Another interesting therapeutic option is rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B-lymphocytes. Administration of rituximab for patients with PNP in combination with follicular NHL is not always successful regarding oral lesions as we report in this case. PE leading to prompt depletion of autoreactive antibodies combined with immunosuppressants or synchronisation of PE with IVIg seems the best treatment modality for this refractory group, but the therapeutic value and appropriate timing of rituximab obviously deserve further evaluation in patients with low grade NHL and PNP.

show abstract

“…In several subsequent articles, DCP therapy has been reviewed and modified. [3][4][5][6][7][8][9][10][11] …”

Section: Introductionmentioning

confidence: 99%